Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-03-28, Stock:ABBV, The news for the past five days is as follows:
2018-03-21: NEWS1: iShares Core S&P Total U.S. Stock Market ETF Experiences Big Inflow.NEWS2: iShares Core S&P Total U.S. Stock Market ETF Experiences Big Inflow.NEWS3: Drug prices continue to climb despite barrage of criticism.NEWS4: AbbVie and the International Myeloma Foundation Announce Partnership to Study the Role of a Genetic Mutation in Outcomes of Patients with Multiple Myeloma.
2018-03-22: NEWS1: ABBV Let Down By TRINITY, ODT Down 10% So Far This Month, NCNA On Watch.NEWS2: ABBV Let Down By TRINITY, ODT Down 10% So Far This Month, NCNA On Watch.NEWS3: What Happened in the Stock Market Today.NEWS4: What Happened in the Stock Market Today.NEWS5: AbbVie Inc Stock Dives on Lung Cancer Drug Results.NEWS6: AbbVie Inc Stock Dives on Lung Cancer Drug Results.NEWS7: What Happened in the Stock Market Today.NEWS8: US STOCKS-Stocks tumble to worst day in six weeks after Trump tariff action.NEWS9: The Biggest Movers: Everyone Loves Utilities.NEWS10: Caterpillar and Bank of America sink; Guess surges.NEWS11: Health Care Sector Update for 03/22/2018: ABBV,SNGX,RETA,AVDL.NEWS12: Health Care Sector Update for 03/22/2018: ABBV,SNGX,RETA,AVDL.NEWS13: Stock Market Dives On Trade War Fears As China, Chip Stocks Hit Hard.NEWS14: AbbVie (ABBV) Shares Cross 4% Yield Mark.NEWS15: AbbVie (ABBV) Shares Cross 4% Yield Mark.NEWS16: AbbVie Inc. -- Moody's: AbbVie's Rova-T results credit negative.NEWS17: A $158 Billion Drug Giant Faces an Identity Crisis.NEWS18: A $158 Billion Drug Giant Faces an Identity Crisis.NEWS19: AbbVie Tumbles 12% on Drug Reversal.NEWS20: AbbVie's Cancer Drug Setback Provides Buying Opportunity.NEWS21: Why Is AbbVie (ABBV) Stock Crashing Today?.NEWS22: Why Is AbbVie (ABBV) Stock Crashing Today?.NEWS23: RSI Alert: AbbVie (ABBV) Now Oversold.NEWS24: RSI Alert: AbbVie (ABBV) Now Oversold.NEWS25: S&P 500 Movers: ABBV, CMG.NEWS26: S&P 500 Movers: ABBV, CMG.NEWS27: AbbVie's Lung Cancer Drug Falls Short in Tests.NEWS28: Peter Thiel's Firm Backed A Biotech. Big Pharma Bought It. It Blew Up.NEWS29: This Explains Why AbbVie Is Falling Today.NEWS30: This Explains Why AbbVie Is Falling Today.NEWS31: AbbVie Inc Stock Dives on Lung Cancer Drug Results.NEWS32: Why Is AbbVie (ABBV) Stock Crashing Today?.NEWS33: AbbVie's lung cancer drug data disappoints; shares slump.NEWS34: Morning Movers: Dow Drops 300 Points Because Tariffs Are Scarier Than the Fed.NEWS35: Morning Movers: Dow Drops 300 Points Because Tariffs Are Scarier Than the Fed.NEWS36: This Explains Why AbbVie Is Falling Today.NEWS37: How Gilead’s HCV Drugs Performed in 2017.NEWS38: UPDATE: AbbVie shares plummet 11.7% on cancer drug results.NEWS39: Stocks to Watch: Facebook, Amazon, AbbVie, Accenture, Darden, Pandora, Conagra, Guess.NEWS40: How Did Gilead’s HIV Drugs Perform in 4Q17 and 2017?.NEWS41: AbbVie Announces Results from Phase 2 Study Evaluating Rovalpituzumab Tesirine (Rova-T) for Third-Line Treatment of Patients with DLL3-Expressing Relapsed/Refractory Small Cell Lung Cancer.NEWS42: AbbVie (ABBV) Is Losing Ground On Phase 2 Study Results.NEWS43: AbbVie (ABBV) Is Losing Ground On Phase 2 Study Results.NEWS44: [$$] AbbVie: getting over Rova.NEWS45: [$$] AbbVie in $25bn wipeout after cancer drug results.
2018-03-23: NEWS1: Is AbbVie &apos;Unraveling&apos; In Solid Tumor Market After Drug Misstep?.NEWS2: Pharma Stock Roundup: ABBV&apos;s Rova-T Disappoints, J&J Unit Gets Buyout Offer.NEWS3: Cancer Space Roundup: NVS' Tasigna & SGEN's Adcetris Label Expansions in Focus.NEWS4: Cancer Space Roundup: NVS' Tasigna & SGEN's Adcetris Label Expansions in Focus.NEWS5: 5 Dividend Aristocrats Where Analysts See Capital Gains.NEWS6: 5 Dividend Aristocrats Where Analysts See Capital Gains.NEWS7: Cancer Space Roundup: NVS&apos; Tasigna & SGEN&apos;s Adcetris Label Expansions in Focus.NEWS8: Is AbbVie Still a Buy After Its Rova-T Setback?.NEWS9: Is AbbVie Still a Buy After Its Rova-T Setback?.NEWS10: The Implied Analyst 12-Month Target For SPMO.NEWS11: The Implied Analyst 12-Month Target For SPMO.NEWS12: AbbVie (ABBV) Stock Falls on Weak Lung Cancer Study Outcome.NEWS13: AbbVie (ABBV) Stock Falls on Weak Lung Cancer Study Outcome.NEWS14: How Gilead Sciences’ Ranexa, AmBisome, Zydelig, and Vosevi Performed.NEWS15: Is AbbVie Still a Buy After Its Rova-T Setback?.NEWS16: AbbVie: Biggest Loss in the S&P 500 on March 22.NEWS17: AbbVie stock slammed after disappointing results for cancer drug acquired in $5.8 billion deal.NEWS18: AbbVie stock slammed after disappointing results for cancer drug acquired in $5.8 billion deal.NEWS19: Today’s Research Reports on Stocks to Watch: AbbVie and Pfizer.NEWS20: AbbVie’s latest trial data was probably worse than it looked.NEWS21: AbbVie’s latest trial data was probably worse than it looked.NEWS22: AbbVie (ABBV) Stock Falls on Weak Lung Cancer Study Outcome.NEWS23: Is The AbbVie Dip A Buying Opportunity?.NEWS24: Asian shares slump on fears of trade war between US, China.NEWS25: Asian shares slump on fears of trade war between US, China.NEWS26: Is It Game Over for AbbVie's Promising Cancer Drug?.NEWS27: Is It Game Over for AbbVie's Promising Cancer Drug?.NEWS28: Is It Game Over for AbbVie&apos;s Promising Cancer Drug?.NEWS29: AbbVie Dip Presents Rare Buying Opportunity; Activist Steps Up at SuperValu.
2018-03-26: NEWS1: U.S. jury orders AbbVie to pay $3 mln in AndroGel retrial.NEWS2: The Biggest Movers: Microsoft Shines; AbbVie Slumps.NEWS3: Monday's ETF with Unusual Volume: XMX.NEWS4: Monday's ETF with Unusual Volume: XMX.NEWS5: Exploring Xencor’s Cash Flows.NEWS6: Analysts’ Recommendations for Xencor and Its Peers in March.NEWS7: The Zacks Analyst Blog Highlights: AbbVie, J&J, Heron Therapeutics, Roche and Pfizer.NEWS8: The Zacks Analyst Blog Highlights: AbbVie, J&J, Heron Therapeutics, Roche and Pfizer.NEWS9: The Zacks Analyst Blog Highlights: AbbVie, J&J, Heron Therapeutics, Roche and Pfizer.
2018-03-27: NEWS1: How Risky Is AbbVie's Pipeline?.NEWS2: How Risky Is AbbVie's Pipeline?.NEWS3: How Risky Is AbbVie&apos;s Pipeline?.

Answer: Rise